MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Patients With IBS-D

NCT06247046 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1298

Last updated 2025-04-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Live SK08 Powder compared with placebo in the treatment of participants with irritable bowel syndrome with diarrhea.

Conditions

  • Irritable Bowel Syndrome With Diarrhea

Interventions

DRUG

Live SK08 powder

Oral Powder

DRUG

Placebo

Oral Powder

Sponsors & Collaborators

  • Guangzhou Zhiyi Biotechnology Co., Ltd.

    lead OTHER

Principal Investigators

  • Minhu Chen, Doctor · First Affiliated Hospital, Sun Yat-Sen University

  • Yinglian Xiao, Doctor · First Affiliated Hospital, Sun Yat-Sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-16
Primary Completion
2026-04-30
Completion
2027-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06247046 on ClinicalTrials.gov